Zinman B, et al. Cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28. https://doi.org/10.1056/NEJMoa1504720. Empagliflozin.

Article  CAS  PubMed  Google Scholar 

Mahaffey KW, et al. Canagliflozin for primary and Secondary Prevention of Cardiovascular Events: results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation. 2018;137:323–34. https://doi.org/10.1161/CIRCULATIONAHA.117.032038.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wiviott SD, et al. Dapagliflozin and Cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347–57. https://doi.org/10.1056/NEJMoa1812389.

Article  CAS  PubMed  Google Scholar 

Heerspink HJL, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436–46. https://doi.org/10.1056/NEJMoa2024816.

Article  CAS  PubMed  Google Scholar 

Ni L, Yuan C, Chen G, Zhang C, Wu X. SGLT2i: beyond the glucose-lowering effect. Cardiovasc Diabetol. 2020;19:98. https://doi.org/10.1186/s12933-020-01071-y.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hallow KM, Helmlinger G, Greasley PJ, McMurray JJV, Boulton DW. Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diabetes Obes Metab. 2018;20:479–87. https://doi.org/10.1111/dom.13126.

Article  CAS  PubMed  Google Scholar 

Zaawari A, Sahar AN. Sodium-glucose co-transporter-2 inhibitors (SGLT2I): a class of drugs with promising cardiorenal protective effects beyond glycemic control. Ann Med Surg (Lond). 2022;81:104536. https://doi.org/10.1016/j.amsu.2022.104536.

Article  PubMed  Google Scholar 

Leccisotti L, et al. Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report. Cardiovasc Diabetol. 2022;21:173. https://doi.org/10.1186/s12933-022-01607-4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cinti F, et al. Dapagliflozin treatment is associated with a reduction of epicardial adipose tissue thickness and epicardial glucose uptake in human type 2 diabetes. Cardiovasc Diabetol. 2023;22:349. https://doi.org/10.1186/s12933-023-02091-0.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sorice GP, et al. Effect of Dapagliflozin on myocardial insulin sensitivity and perfusion: Rationale and Design of the DAPAHEART Trial. Diabetes Ther. 2021;12:2101–13. https://doi.org/10.1007/s13300-021-01083-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li L, et al. SGLT2i alleviates epicardial adipose tissue inflammation by modulating ketone body-glyceraldehyde-3-phosphate dehydrogenase malonylation pathway. J Cardiovasc Med (Hagerstown). 2023;24:232–43. https://doi.org/10.2459/JCM.0000000000001453.

Article  CAS  PubMed  Google Scholar 

Hotamisligil GS. Inflammation, metaflammation and immunometabolic disorders. Nature. 2017;542:177–85. https://doi.org/10.1038/nature21363.

Article  CAS  PubMed  Google Scholar 

The L. Treating obesity and diabetes: drugs alone are not enough. Lancet. 2024;403:1. https://doi.org/10.1016/S0140-6736(24)00003-5.

Article  Google Scholar 

Melson E, Ashraf U, Papamargaritis D, Davies MJ. What is the pipeline for future medications for obesity? Int J Obes (Lond). 2024. https://doi.org/10.1038/s41366-024-01473-y.

Article  PubMed  Google Scholar 

Caruso I, et al. Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis. EClinicalMedicine. 2023;64:102181. https://doi.org/10.1016/j.eclinm.2023.102181.

Article  PubMed  PubMed Central  Google Scholar 

Padda IS, Mahtani AU, Parmar M. in StatPearls (2024).

Jiang M, Steyger PS. An evaluation of US patent 2015065565 (A1) for a new class of SGLT2 inhibitors for treatment 1 of type II diabetes mellitus. Expert Opin Ther Pat. 2015;25:1349–52. https://doi.org/10.1517/13543776.2015.1076392.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Giugliano D, et al. SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs. Cardiovasc Diabetol. 2021;20:236. https://doi.org/10.1186/s12933-021-01430-3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Davies MJ, et al. Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes. Cardiovasc Diabetol. 2022;21:144. https://doi.org/10.1186/s12933-022-01575-9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gao M, et al. SGLT2 inhibitors, functional capacity, and quality of life in patients with heart failure: a systematic review and Meta-analysis. JAMA Netw Open. 2024;7:e245135. https://doi.org/10.1001/jamanetworkopen.2024.5135.

Article  PubMed  PubMed Central  Google Scholar 

Vallon V. State-of-the-art-review mechanisms of action of SGLT2 inhibitors and clinical implications. Am J Hypertens. 2024. https://doi.org/10.1093/ajh/hpae092.

Article  PubMed  Google Scholar 

Ferrannini G, et al. Energy Balance after Sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38:1730–5. https://doi.org/10.2337/dc15-0355.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Giordano A, et al. The adipose organ is a Unitary structure in mice and humans. Biomedicines. 2022;10. https://doi.org/10.3390/biomedicines10092275.

Cinti S. Pink adipocytes. Trends Endocrinol Metab. 2018;29:651–66. https://doi.org/10.1016/j.tem.2018.05.007.

Article  CAS  PubMed  Google Scholar 

Cinti S. Adipose Organ Development and Remodeling. Compr Physiol. 2018;8:1357–431. https://doi.org/10.1002/cphy.c170042.

Article  PubMed  Google Scholar 

Zhang Y, et al. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372:425–32. https://doi.org/10.1038/372425a0.

Article  CAS  PubMed  Google Scholar 

Duerrschmid C, et al. Asprosin is a centrally acting orexigenic hormone. Nat Med. 2017;23:1444–53. https://doi.org/10.1038/nm.4432.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Frontini A, et al. Thymus uncoupling protein 1 is exclusive to typical brown adipocytes and is not found in thymocytes. J Histochem Cytochem. 2007;55:183–9. https://doi.org/10.1369/jhc.6A7013.2006.

Article  CAS  PubMed  Google Scholar 

Cannon B, Nedergaard J. Brown adipose tissue: function and physiological significance. Physiol Rev. 2004;84:277–359. https://doi.org/10.1152/physrev.00015.2003.

Article  CAS  PubMed  Google Scholar 

Giralt M, Cereijo R, Villarroya F. Adipokines and the endocrine role of adipose tissues. Handb Exp Pharmacol. 2016;233:265–82. https://doi.org/10.1007/164_2015_6.

Article  CAS  PubMed